Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Status: Active


A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.

Eligibility Criteria

Inclusion Criteria

  • All patients participating in this clinical trial must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or appropriate.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • Presence of at least one measurable lesion according to RECIST v1.1.
  • Documented MAPK alteration Additional inclusion criteria for the Dose Expansion part: LXH254 in combination with PDR001:
  • Patients with confirmed KRAS-mutated NSCLC
  • Patients with confirmed NRAS-mutated melanoma

Exclusion Criteria

  • Prior treatment with a BRAFi, MEKi and/or pan-RAF inihibitors for patients to be enrolled in the dose expansion part. Exceptions may be made after documented agreement between Novartis and Investigator.
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.
  • Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
  • Patients receiving proton pump inhibitors which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study.
  • Pregnant or nursing (lactating) women Additional exclusion criteria for LXH254 in combination with PDR001
  • History of severe hypersensitivity reactions, which in the opinion of the investigator may cause in increased risk of serious infusion reaction.
  • Known human immunodeficiency virus (HIV).
  • Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection.
  • Active, known or suspected autoimmune disease.
  • Active infection requiring systemic antibiotic therapy
  • Patients requiring systemic steroid therapy or any immunosuppressive therapy (≥10mg/day prednisone or equivalent) which cannot be discontinued at least 7 days prior to first dose of study treatment.
  • Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.

Locations & Contacts


Dana-Farber Cancer Institute
Status: Active
Name Not Available
Massachusetts General Hospital Cancer Center
Status: Active
Contact: Ibiayi Dagogo-Jack
Phone: 617-724-4000

New York

New York
Memorial Sloan Kettering Cancer Center
Status: Active
Name Not Available


M D Anderson Cancer Center
Status: Active
Name Not Available

Trial Phase & Type

Trial Phase

Phase I

Trial Type


Lead Organization

Lead Organization
Novartis Pharmaceuticals Corporation

Trial IDs

Primary ID CLXH254X2101
Secondary IDs NCI-2015-02280, 2015-003421-33 ID NCT02607813